Dako, an Agilent Technologies Company, announces expanded collaboration with Amgen within companion diagnostics
March 24 2015 - 9:10AM
Dako, an Agilent Technologies company
and a worldwide provider
of cancer diagnostics, today announced a new
Master Collaboration Agreement with Amgen Inc., a leading
biotechnology company.
The expanded collaboration will allow both
companies to benefit from knowledge-sharing within the field of
drug-diagnostic research and development in general, and in
relation to companion diagnostic products in particular. This
collaboration is important in the area of personalized medicine,
where targeted treatments and companion diagnostics can help
identify patients for whom a particular treatment may work, leading
to improved patient care and more manageable healthcare costs.
"We are proud to both continue and broaden our
multi-year partnership with Amgen," said Jacob Thaysen, president
of Agilent's Diagnostics and Genomics Group. "Together we will
continue our work in the development of high-quality companion
diagnostic products to enable physicians and pathologists to
identify cancer patients who are more likely to respond to a
specific therapy."
Today's announcement follows several other
collaborative agreements in the companion diagnostics area.
Agilent's Dako business has partnerships with several top-tier
pharma companies for the development of companion diagnostics. Its
track record and experience in companion diagnostic development
continues to attract new partners, as well as add new projects with
current partners.
The financial details of the agreement were not
disclosed.
About Agilent Technologies and Dako Agilent
Technologies Inc. (NYSE:A), a global leader in life sciences,
diagnostics and applied chemical markets, is the premier laboratory
partner for a better world. Agilent works with customers in more
than 100 countries, providing instruments, software, services and
consumables for the entire laboratory workflow. Agilent generated
revenues of $4.0 billion in fiscal 2014. The company employs about
12,000 people worldwide. In 2012, Agilent acquired Dako, a
well-known provider of reagents, instruments, software and
expertise to make accurate diagnoses and determine the most
effective treatment for cancer patients. Information about Agilent
is available at www.agilent.com and information about Dako is
available at www.dako.com.
Editorial Contacts Agilent Media and Press Victoria
Wadsworth-Hansen Phone: +45 29336980 Email:
victoria.wadsworth-hansen@agilent.com
HUG#1905576
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024